Study Complete
Sponsor ID
CFZ001
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients with Multiple Myeloma and Renal Disease
Study Details
The purpose of this study is to see how the body and the cancer react to carfilzomib, including measuring the amount of the study drug in the blood at certain times following dosing. This study is being done in people with normal kidney function and those with end-stage renal disease to see if they respond differently to the study drug.
Protocol Summary
Primary Outcome Measures
Not Available
Secondary Outcome Measures
Not Available
Locations
Location
Gabrail Cancer Center
Canton, OH, United States
Status
Recruiting
Location
Sir Mortimer B. Davis-Jewish General Hospital
Montreal, Quebec, Canada
Status
Recruiting
Location
Karmanos Cancer Institute
Detroit, MI, United States
Status
Recruiting
Location
UT Southwestern Medical Center
Dallas, TX, United States
Status
Recruiting
Location
Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
Status
Recruiting
Location
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada
Status
Recruiting
Showing {first} - {last} of {total} Results